A recent study published in Psychiatric Services in Advance has revealed that adults with schizophrenia spectrum disorders face high rates of comorbid mental and substance use disorders, as well as significant social and economic disadvantages. According to the research, only 26% of individuals with these disorders received minimally adequate treatment. The authors of the study, led by Natalie Bareis, Ph.D., from Columbia University Irving Medical Center and New York State Psychiatric Institute, argue that innovative interventions and implementation strategies are needed to improve access to and use of evidence-based approaches for this population.
The research, conducted using national data collected from 4,764 adults aged 18 to 65 in the U.S. Mental and Substance Use Disorders Prevalence Study (MDPS) from Oct. 2020 to Oct. 2022, compared sociodemographic characteristics and comorbid behavioral health conditions of individuals with or without schizophrenia spectrum disorders. Among the 114 adults with schizophrenia spectrum disorders in the study, the most common comorbid conditions were major depressive episode (52%), alcohol use (23%), cannabis use (20%), and posttraumatic stress disorders (17%). Individuals with schizophrenia spectrum disorders were also found to be significantly more likely to experience suicidal ideation and suicide attempts in the past year compared to those without these disorders.
Despite the fact that almost all participants with schizophrenia spectrum disorders had health care coverage, only around 70% had received any type of mental health treatment in the past year, and approximately 30% were currently taking an antipsychotic medication. The study also revealed that a large number of individuals with schizophrenia spectrum disorders were unemployed and experiencing serious functional impairment, despite the availability of effective treatments and services such as antipsychotic medications, individual placement and support, assertive community treatment, and coordinated specialty care for first-episode psychosis.
Bareis emphasized the importance of the MDPS in updating decades-old surveys of psychiatric disorders in the U.S., particularly in its focus on identifying schizophrenia spectrum disorders through the use of structured clinical interviews. However, the findings of the study indicate that despite advancements in treatments and services, the circumstances of individuals with schizophrenia spectrum disorders have not significantly improved. Persistent high rates of poverty, unemployment, and poor functioning suggest that current treatment and social welfare approaches may not be effectively meeting the needs of this population. Bareis argues that policies aimed at improving access to and utilization of existing evidence-based interventions are crucial in addressing these challenges.
In conclusion, the study highlights the urgent need for improved strategies to address the complex needs of individuals with schizophrenia spectrum disorders. By implementing innovative interventions and policies to enhance access to and utilization of evidence-based treatments, it is hoped that the social and economic disadvantages faced by this population can be reduced. Further research and collaboration among stakeholders will be essential in developing a comprehensive approach to support individuals with schizophrenia spectrum disorders and improve their overall well-being.
